NCT06881446View on ClinicalTrials.gov

Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/tyrosine Kinase Inhibitors with or Without TACE for Advanced HCC with Vascular Invasions

RecruitingOBSERVATIONAL
Enrollment

1,200

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

June 30, 2025

Study Completion Date

July 30, 2025

Conditions
Hepatocellular Carcinoma (HCC)
Trial Locations (1)

Unknown

RECRUITING

Zhongda Hospital, Nanjing

All Listed Sponsors
lead

Zhongda Hospital

OTHER